NM_015391.4:c.100-1281A>G
Variant names:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_015391.4(ANAPC13):c.100-1281A>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.151 in 152,258 control chromosomes in the GnomAD database, including 1,797 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.15 ( 1797 hom., cov: 33)
Consequence
ANAPC13
NM_015391.4 intron
NM_015391.4 intron
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: -0.619
Publications
3 publications found
Genes affected
ANAPC13 (HGNC:24540): (anaphase promoting complex subunit 13) This gene encodes a component of the anaphase promoting complex, a large ubiquitin-protein ligase that controls cell cycle progression by regulating the degradation of cell cycle regulators such as B-type cyclins. The encoded protein is evolutionarily conserved and is required for the integrity and ubiquitin ligase activity of the anaphase promoting complex. Pseudogenes and splice variants have been found for this gene; however, the biological validity of some of the splice variants has not been determined. [provided by RefSeq, Nov 2008]
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.88).
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.192 is higher than 0.05.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| ANAPC13 | NM_015391.4 | c.100-1281A>G | intron_variant | Intron 2 of 2 | ENST00000354910.10 | NP_056206.1 | ||
| ANAPC13 | NM_001242374.1 | c.100-1281A>G | intron_variant | Intron 2 of 2 | NP_001229303.1 | |||
| ANAPC13 | NM_001242375.1 | c.100-1281A>G | intron_variant | Intron 2 of 2 | NP_001229304.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.151 AC: 23028AN: 152140Hom.: 1794 Cov.: 33 show subpopulations
GnomAD3 genomes
AF:
AC:
23028
AN:
152140
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome AF: 0.151 AC: 23035AN: 152258Hom.: 1797 Cov.: 33 AF XY: 0.154 AC XY: 11434AN XY: 74442 show subpopulations
GnomAD4 genome
AF:
AC:
23035
AN:
152258
Hom.:
Cov.:
33
AF XY:
AC XY:
11434
AN XY:
74442
show subpopulations
African (AFR)
AF:
AC:
5230
AN:
41566
American (AMR)
AF:
AC:
2257
AN:
15294
Ashkenazi Jewish (ASJ)
AF:
AC:
359
AN:
3472
East Asian (EAS)
AF:
AC:
1046
AN:
5182
South Asian (SAS)
AF:
AC:
887
AN:
4828
European-Finnish (FIN)
AF:
AC:
2295
AN:
10580
Middle Eastern (MID)
AF:
AC:
24
AN:
294
European-Non Finnish (NFE)
AF:
AC:
10553
AN:
68016
Other (OTH)
AF:
AC:
287
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.499
Heterozygous variant carriers
0
995
1990
2986
3981
4976
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
252
504
756
1008
1260
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
736
AN:
3476
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.